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ABSTRACT: We examined the eﬀects of isoform-speciﬁc
histone deacetylase (HDAC) inhibitors on β-catenin post-
translational modiﬁcations in neural progenitor cells (NPCs)
derived from human induced pluripotent stem cells (iPSCs).
β-catenin is a multifunctional protein with important roles in
the developing and adult central nervous system. Activation of
the Wnt pathway results in stabilization and nuclear trans-
location of β-catenin, resulting in activation of multiple target
genes. In addition, β-catenin forms a complex with cadherins at
the plasma membrane as part of the adherens junctions. The
N-terminus of β-catenin has phosphorylation, ubiquitination,
and acetylation sites that regulate its stability and signaling. In
the absence of a Wnt signal, Ser33, Ser37, and Thr41 are constitutively phosphorylated by glycogen synthase kinase 3β (GSK3β).
β-Catenin phosphorylated at these sites is recognized by β-transducin repeat-containing protein (βTrCP), which results in
ubiquitination and degradation by the ubiquitin-proteasome pathway. The N-terminal regulatory domain of β-catenin also
includes Ser45, a phosphorylation site for Casein Kinase 1α (CK1α) and Lys49, which is acetylated by the acetyltransferase
p300/CBP-associated factor (PCAF). The relevance of Lys49 acetylation and Ser45 phosphorylation to the function of β-catenin
is an active area of investigation. We ﬁnd that HDAC6 inhibitors increase Lys49 acetylation and Ser45 phosphorylation but do
not aﬀect Ser33, Ser37, and Thr41 phosphorylation. Lys49 acetylation results in decreased ubiquitination of β-catenin in the
presence of proteasome inhibition. While increased Lys49 acetylation does not aﬀect total levels of β-catenin, it results in
increased membrane localization of β-catenin.
β-Catenin is an evolutionarily conserved protein that is relevant
in many diﬀerent cellular contexts, including vital ones in the
human central nervous system.1−3 The canonical Wnt pathway
plays an important role in the proliferation and diﬀerentiation
of neural stem cells.4 β-catenin is an integral component of the
Wnt signaling pathway.4,5 When the Wnt pathway is not active,
β-catenin is retained in the cytoplasm in a “destruction
complex” with Axin, adenomatous polyposis coli (APC) and
GSK3β.6,7 In this complex, β-catenin is constitutively
phosphorylated by GSK3β. This phosphorylated version of β-
catenin is recognized by βTrCP of the E3 ubiquitin ligase
complex and degraded by the proteasome.7 When the Wnt
pathway is active, Wnt ligands bind to the Frizzled/LRP
receptor complex, and Axin is recruited to the membrane by
phosphorylated LRP, resulting in the dismantling of the
destruction complex.8 β-Catenin then accumulates and trans-
locates to the nucleus, where it binds to the T-cell factor (TCF)
family of transcription factors and increases transcription of a
number of target genes.9 In addition to the central role in the
Wnt signaling pathway, β-catenin also forms a complex with
cadherins at the plasma membrane as part of the adherens
junctions, including with N-cadherin in neuronal cells.2,3,10 The
β-catenin/N-cadherin complex plays an important role in cell−
cell adhesion in the nervous system and is present in both pre-
and postsynaptic cells.2,3,10,11
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Human β-catenin consists of 781 amino acids that can be
divided into three regionsa central region that comprises 12
Armadillo repeats, an N-terminal regulatory domain, and a C-
terminal domain that binds transcription factors.2 The
structurally ﬂexible N-terminal regulatory domain includes
sites for posttranslational modiﬁcation that regulate the stability
and function of β-catenin. GSK3β phosphorylates Ser33, Ser37,
and Thr41 and primes β-catenin for degradation by βTrCP-
mediated ubiquitination.1 CK1α phosphorylates Ser45 but the
functional consequence of this phosphorylation is not well
understood.12 One model posits that phosphorylation of Ser45
primes β-catenin for GSK3β phosphorylation of Ser33, Ser37,
and Thr41.13−15 However, other reports note that Ser45
phosphorylation is uncoupled from phosphorylation of Ser33,
Ser37, and Thr41.16−19
HDACs and HATs (histone acetyltransferases) have been
studied extensively for their role in regulating chromatin
function by modulating acetylation of histone proteins.20,21 In
addition, there is a growing recognition of cellular processes
where HDACs play crucial roles by deacetylating nonhistone
proteins.22−24 One such instance is the acetylation of lysine
residues on β-catenin. Lys49 is a posttranslational modiﬁcation
site on β-catenin that can be acetylated.25−27 This acetylation
site is adjacent to phosphorylation sites for CK1α and GSK3β
in the N-terminal regulatory domain. Lys49 has been found to
be mutated to arginine in anaplastic thyroid carcinomas,
resulting in increased nuclear localization of β-catenin.28 In the
cancer cell lines SW480 and HCT116, it was shown that Lys49
deacetylation was necessary for epidermal growth factor
(EGF)-induced nuclear localization of β-catenin.29 However,
outside of these tumor cell lines, the function and regulation of
this acetylation site remains poorly understood.
HDACs have important roles in the central nervous system,
especially in learning and memory and in the regulation of
synaptic plasticity.30−33 Most HDAC inhibitors studied to date
in neuronal cells have broad selectivity and target multiple
HDAC isoforms.34 Recent advances in chemical biology
approaches have led to a better understanding of diﬀerent
HDAC isoforms and development of small-molecule probes
that target speciﬁc HDAC isoforms.35,36 While many of these
studies on HDACs have focused on class I HDACs (HDACs
1,2,3) located in the nucleus, there have been signiﬁcant
advances in the design of novel inhibitors that target the
cytoplasmic IIb HDAC, HDAC6.36−42 These eﬀorts have led to
the development of multiple small molecules with diﬀerent
chemical scaﬀolds that are highly selective for HDAC6 and
allow for speciﬁc inhibition of HDAC6 at the cellular level.42−49
Here, we report on studies designed to investigate the nature
of Lys49 acetylation in human iPSC-derived NPCs. We tested a
set of annotated isoform-speciﬁc HDAC inhibitors to identify
the HDAC isoform that deacetylates Lys49. We show that only
small molecules that can inhibit HDAC6 result in increased
Lys49 acetylation. We ﬁnd that Lys49 acetylation is
accompanied by increase in Ser45 phosphorylation without
aﬀecting the phosphorylation of the Ser33, Ser37, Thr41 sites.
Lys49 acetylation is also accompanied by decreased ubiquiti-
nation of β-catenin in the presence of proteasomal inhibition.
We ﬁnd that Lys49 acetylation does not alter overall levels of β-
catenin in these human NPCs but results in increased
membrane localization of β-catenin pointing to a novel
mechanism for diﬀerentially regulating the function of β-
catenin in distinct subcellular compartments.
Figure 1. HDAC inhibitors used in the study. Structures of the small molecule inhibitors used in the study. The HDAC speciﬁcity of the small
molecules are as follows: SAHA (HDAC 1, 2, 3, 6, 8), crebinostat (HDAC 1, 2, 3, 6), CI-994 (HDAC 1, 2, 3), Cpd-60 (HDAC 1, 2), BG-45
(HDAC3), tubacin (HDAC6), ACY-1215 (HDAC6), tubastatin A (HDAC6), PCI-34051 (HDAC8). IC50 values (μM) of the small molecules for
inhibition of diﬀerent HDAC isoforms are showed in Table 1.31,36,37,44,55−57
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■ RESULTS AND DISCUSSION
Eﬀect of Diﬀerent HDAC Inhibitors on Lys49
Acetylation on β-Catenin. We undertook experiments to
dissect the nature of Lys49 acetylation in the human neuronal
context by undertaking experiments in human iPSC-derived
NPCs. In order to identify the HDAC isoform that deacetylates
Lys49 in human NPCs, we used a set of annotated HDAC
inhibitors that are selective for speciﬁc HDAC isoforms (Figure
1, Table 1).35,36 Under basal conditions, these human NPCs
had minimal Ac-Lys49 β-catenin present, as measured by
Western blotting of whole-cell extracts (Figure 2A). Treatment
with the pan-HDAC inhibitor SAHA led to a marked increase
in the level of Ac-Lys49 β-catenin (Figure 2A). We observed
similar results with crebinostat, which inhibits HDACs 1, 2, 3,
and 6.31 However, inhibitors speciﬁc for class I HDACs, such as
CI-994, which inhibits HDACs 1, 2, and 3, Cpd-60, which
inhibits HDACs 1 and 2, and BG-45, which preferentially
inhibits HDAC3, did not increase levels of Ac-Lys49 β-catenin.
In contrast, treatment with three structurally distinct HDAC6
inhibitorstubacin, tubastatin A, and ACY-1215resulted in
marked increase in Ac-Lys49 β-catenin levels (Figure 2A). We
repeated the experiment in a second human iPSC-derived NPC
line 8330 and again found that only compounds that inhibit
HDAC6 increased Ac-Lys49 β-catenin levels (Figure 2B).50
The increase in Ac-Lys49 β-catenin in response to HDAC6
inhibition could be observed within 2 h of treatment (Figure
2C). While HDAC6 inhibitors increased levels of Ac-Lys49 β-
catenin, there was no change in overall levels of β-catenin in the
NPCs (Figure 2).
Eﬀect of HDAC6 Inhibitor-Mediated β-Catenin Lys49
Acetylation on N-Terminal Posttranslational Modiﬁca-
tion Sites. We investigated how Lys49 acetylation on β-
catenin aﬀected the adjacent posttranslational modiﬁcation sites
in the N-terminal regulatory domain. At baseline, there was
minimal Ser45 phosphorylation on β-catenin in the NPCs
(Figure 3A). We found that the increase in Lys49 acetylation in
response to HDAC6 inhibitors was mirrored by an increase in
Ser45 phosphorylation that followed a similar time course
(Figure 3A, B). We also carried out functional genomic studies
with siRNA knockdown to conﬁrm these ﬁndings. In the
presence of HDAC6 knockdown, we again observed an
increase in Lys49 acetylation and Ser45 phosphorylation.
(Figure 3C, D). We next determined how Lys49 acetylation
aﬀected the GSK3β phosphorylation sites on β-catenin by
examining levels of β-catenin phosphorylated at Ser33, Ser37,
and Thr41. In the presence of the HDAC6 inhibitor ACY-1215,
the increased levels of Ac-Lys49 β-catenin had no eﬀect on the
levels for β-catenin phosphorylated at Ser33, Ser37, and Thr41
(Figure 3A, B). These results suggest that Lys49 acetylation
increases the ability of CK1α to bind and phosphorylate Ser45
on β-catenin while preventing GSK3β from phosphorylating its
target sites Ser33, Ser37, and Thr41. The exact mechanisms
behind these eﬀects on the phosphorylation sites remain to be
elucidated. Our results show that Lys49 acetylation is
Table 1. IC50 Values (μM) of the Small Molecules for Inhibition of Diﬀerent HDAC Isoforms
31,36,37,44,55−57
HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC selectivity
SAHA 0.0013 0.0016 0.005 3.6 0.0016 0.48 1, 2, 3, 6, 8
crebinostat 0.0007 0.001 0.002 0.009 1, 2, 3, 6
CI-994 0.05 0.19 0.55 1, 2, 3
Cpd-60 0.001 0.008 0.458 1, 2
BG-45 2 2.2 0.289 >20 3
tubacin 0.028 0.042 0.275 17 1.5 0.016 8.5 0.17 6
ACY-1215 0.058 0.048 0.051 7 5 0.004 1.4 0.1 10 6
tubastatin A 3.2 3.5 4.9 0.018 6
PCI-34051 >50 >50 6.8 2.9 0.01 >50 8
Figure 2. Eﬀect of HDAC inhibitors on β-catenin Lys49 acetylation.
(A) Immunoblot analysis of lysates from human NPCs treated with
diﬀerent HDAC inhibitors at 5 μM for 18 h, with Western blot using
antibodies against β-catenin and Ac-Lys49-β-catenin. β-Actin is shown
as loading control. Antibodies against Ac-α-tubulin (Lys40) are shown
to reﬂect the level of HDAC6 inhibitory activity of each small
molecule. (B) Immunoblot analysis of lysates from a second human
iPSC-derived NPC line (8330NPC) treated similarly with HDAC
inhibitors at 5 μM for 18 h, with Western blot using antibodies against
β-catenin and Ac-Lys49-β-catenin. (C) Time course of increase in Ac-
Lys49-β-catenin treated with the HDAC6-speciﬁc inhibitor ACY-1215
at 10 μM.
ACS Chemical Biology Articles
DOI: 10.1021/cb500838r
ACS Chem. Biol. 2015, 10, 883−890
885
accompanied by both increased CK1α and GSK3β binding,
even though only CK1α is able to phosphorylate its target
residue (Figure 3E).
Ser45 phosphorylation has been hypothesized to be a
priming step for phosphorylation at Ser33, Ser37, and Thr41
and subsequent ubiquitination and proteasomal degrada-
tion.13−15 In the human NPCs, Ac-Lys49 β-catenin was
accompanied by increase in Ser45 but not in Ser33, Ser37
and Thr41 phosphorylation (Figure 3A,B). We also did not ﬁnd
any changes in overall levels of β-catenin. Lys49 is a known site
for ubiquitination, which primes β-catenin for degradation by
the proteasome.51 There have been suggestions of cross-talk
between acetylation and ubiquitination on β-catenin.26 To
explore this possibility, we studied the eﬀect of the proteasome
inhibitor MG-132 in NPCs in the presence or absence of ACY-
1215. When the NPCs were treated with the proteasome
inhibitor MG-132, there was signiﬁcant accumulation of
ubiquitinated β-catenin, along with increase in overall level of
β-catenin (Figure 4). However, when NPCs were pretreated
with the HDAC6 inhibitor ACY-1215, there was minimal
change in levels of ubiquitinated β-catenin or in overall level of
β-catenin in the presence of MG-132. In our experiments, the
lack of increase in overall levels of β-catenin in the presence of
ACY-1215 and MG-132 was surprising. It is possible that the
increased β-catenin may be in the insoluble fractions and hence
not seen in the Western blot. Total ubiquitination levels in cell
lysates was unaﬀected by ACY-1215 pretreatment suggesting
that the eﬀects of ACY-1215 on ubiquitination are speciﬁc
rather than global (Figure 4). Our ﬁndings suggest that
HDAC6 inhibitor-mediated increase in Lys49 acetylation has a
major impact on β-catenin ubiquitination.
Eﬀect of HDAC6 Inhibition on Subcellular Local-
ization of β-Catenin.While increases in Lys49 acetylation did
not result in gross changes in β-catenin levels, we investigated if
it aﬀected subcellular localization of β-catenin in human NPCs.
Acetylation has been shown to modulate subcellular localization
of nonhistone proteins.23 Using immunoﬂuorescence, we found
that both ACY-1215 and siRNA knockdown of HDAC6
induced pronounced increases in β-catenin at the plasma
membrane (Figure 5A, B). To corroborate the results of these
imaging assays, we carried out cell fractionation of NPCs
treated with ACY-1215. These cell fractionation studies showed
that the increase in Ac-Lys49 β-catenin was primarily in the
membrane/cytoplasmic fraction and not in the nuclear fraction
(Figure 5C). We observed that HDAC6 was localized in the
cytoplasmic/membrane fraction and not in the nuclear fraction
(Figure 5C). We also carried out immunoprecipitation
experiments using antibodies against N-cadherin in cells treated
Figure 3. Eﬀect of HDAC6 inhibitor-mediated increase in acetylation
of β-catenin Lys49 on N-terminal posttranslational modiﬁcation sites.
(A) Time-course immunoblot analysis of human NPCs treated with an
HDAC6 inhibitor. Human NPCs were treated with HDAC6 inhibitor
ACY-1215 at 5 μM for the times points indicated and the lysates
immunoblotted with antibodies against β-catenin, Ac-Lys49-β-catenin,
phos-Ser45 and phos-Ser33, Ser37, and Thr41. β-actin is using shown
as loading control. (B) Quantiﬁcation of the intensity of Western blot
band signals from A. in indicated antigens normalized to total β-
catenin before and after treatment with ACY-1215 at 5 μM for 8 h.
Results are representative of three independent experiments. Error
Figure 3. continued
bars indicate standard deviation. ** and *** denote signiﬁcance with p
< 0.01 and p < 0.001, respectively (paired t test). (C)
Immunoﬂuorescence staining for HDAC6 in human NPCs when
treated with control siRNA (left) and HDAC6 siRNA (right). (D)
Immunoblot analysis of lysates from human NPCs treated with
HDAC6 siRNA, control siRNA, and ACY-1215, using antibodies
against HDAC6, β-catenin, Ac-Lys49-β-catenin, and phos-Ser45-β-
catenin. β-actin is shown as loading control. (E) Time course of CK1α
and GSK3β bound to β-catenin bound to in human NPCs treated with
5 μM ACY-1215. Cell lysates were immunoprecipitated with anti-β-
catenin antibody and levels of CK1α and GSK3β were measured by
immunoblot analysis.
ACS Chemical Biology Articles
DOI: 10.1021/cb500838r
ACS Chem. Biol. 2015, 10, 883−890
886
with the HDAC6 inhibitor ACY-1215. While overall levels of β-
catenin bound to N-cadherin did not appear to change in NPCs
treated with ACY-1215, the pool of β-catenin bound to N-
cadherin was enriched for Lys49 acetylation (Figure 5D).
β-Catenin plays important roles in multiple cellular and
disease contexts but much remains to be learned about the
regulation of β-catenin in the diﬀerent cellular contexts,
including pivotal ones in the human central nervous system.1−3
Given the central role of β-catenin in the biology of neural
stem cells, we had carried out studies to dissect the role of
posttranslational modiﬁcations of β-catenin in human iPSC-
derived NPCs, focusing on the Lys49 acetylation site.52 After
systematically testing a set of annotated isoform-selective
HDAC inhibitors and siRNA knockdown, we found that
HDAC6 inhibition alone was suﬃcient to induce Lys49
acetylation whereas selective class I HDAC inhibitors targeting
HDAC1/2/3/8 were ineﬀective. This is consistent with earlier
studies in cancer cell lines where it was shown that HDAC6
activity was necessary for EGF-mediated β-catenin nuclear
localization.29 Lys49 deacetylation was shown to be necessary
for β-catenin nuclear localization in that cancer context, but the
role played by β-catenin acetylated at Lys49 was not known.
We show here that increased β-catenin Lys49 acetylation in
human neuronal cells correlates with an increased localization
of β-catenin at the plasma membrane.
There are a few diﬀerences to note in the HCT116 and
SW480 cancer cell lines that had been used to study the EGF-
mediated nuclear translocation of β-catenin and the human
iPSC-derived NPCs used in this study. In the two cancer cell
lines, there was an abundance of Ac-Lys49 at baseline.29
Activation of the EGF pathway resulted in decreased levels of
Figure 4. Eﬀect of HDAC6 inhibition on ubiquitination of β-catenin.
Immunoblot analysis of ubiquitination in human NPCs. Human NPCs
were treated with 1 μM of the proteasome inhibitor MG-132 for 4 h,
the cell lysates were immunoprecipitated with anti-β-catenin antibody,
and the level of ubiquitination was measured in a Western blot using
an antiubiquitin antibody. Results are also shown for human NPCs
preincubated with 5 μM ACY-1215 for 6 h prior to MG-132
treatment.
Figure 5. Eﬀect of HDAC6 inhibition on membrane localization of β-
catenin. (A, B) Immunoﬂuorescence staining for β-catenin treated
with HDAC6 inhibitor (A) and HDAC6 siRNA (B) in human NPCs.
Cells were treated with 5 μM ACY-1215 or DMSO for 18 h (A) or
with HDAC6 siRNA and control siRNA for 72 h (B) and imaged with
anti-β-catenin antibody (green), anti-β-tubulin antibody (red), and
Hoechst 33342 (blue). Scale bar, 20 μm. Quantiﬁcation of β-catenin
levels at the membrane represent two independent experiments with
three ﬁelds of view each at 20× magniﬁcation. Error bars indicate
standard deviation. ** and **** denote signiﬁcance at p < 0.01 and p
< 0.0001, respectively (unpaired t test). (C) Immunoblot analysis for
nuclear (N) and membrane/cytoplasmic (M/C) fractions for NPCs
treated with HDAC6 inhibitor ACY-1215 (5 μM) or DMSO for 6 h.
Histone H3 is shown as a nuclear marker, GAPDH as a cytoplasmic
marker and integrin β1 as a membrane marker. (D) Immunoblot
analysis for Ac-Lys49-β-catenin bound to N-cadherin. Human NPCs
were treated with ACY-1215 (5 μM) or DMSO for 24 h, lysates
immunoprecipitated with anti-N-cadherin antibody and immunoblot-
ted with antibodies against β-catenin and Ac-Lys49-β-catenin.
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Ac-Lys49, along with increased nuclear staining of β-catenin.29
In the human NPCs we studied, Ac-Lys49 levels were
undetectable at baseline, and there was no noticeable β-catenin
staining in the nucleus suggesting that either p300/CBP
acetylase activity is low or HDAC6 activity is high in NPCs
relative to the cancer cell lines. Upon HDAC6 inhibition, Ac-
Lys49 β-catenin levels increased in NPCs, which was
accompanied by increased membrane localization of β-catenin.
These data emphasize the importance of cellular context for
studying β-catenin function and localization.
The interaction between the diﬀerent posttranslational
modiﬁcation sites in the β-catenin N-terminal regulatory
domain has been an active area of investigation. It is known
that Ser33, Ser37, and Thr41 are phosphorylated by GSK3β,
which creates the binding site for β-TrCP and subsequent
ubiquitination by the E3 ubiquitin ligase system.6,7 What has
not been clear is the interaction between Ser45 and Lys49 with
the GSK3β phosphorylation sites. Ser45 phosphorylation by
CK1α has been described as a priming site for GSK3β
phosphorylation.13−15 However, there have been other reports
that indicated that Ser45 phosphorylation was uncoupled from
the GSK3β phosphorylation sites Ser33, Ser37, and Thr41.16−19
Our results in the human NPCs are supportive of this latter
model as HDAC6 inhibition-induced increase in Lys49
acetylation was accompanied by increase in Ser45 phosphor-
ylation but increased Ser45 phosphorylation was not
accompanied by increased phosphorylation of Ser33, Ser37,
and Thr41. We also found that HDAC6 inhibitor-mediated
increase in Lys49 acetylation and Ser45 phosphorylation led to
decreased ubiquitination in the presence of proteasomal
inhibition. This suggests that the presence of acetylated
Lys49 interferes with ubiquitination of β-catenin.
In summary, we report that multiple structurally distinct
HDAC6 inhibitors, as well as HDAC6 knockdown with siRNA,
led to increased acetylation of Lys49 on β-catenin in human
NPCs. This acetylation increase was accompanied by increased
phosphorylation of the CK1α phosphorylation site but not of
the GSK3β phosphorylation sites. We found that HDAC6
inhibition mediated increase in acetylation of Lys49 on β-
catenin did not change overall levels of β-catenin. However,
increased Lys49 acetylation on β-catenin resulted in increased
membrane localization. We hypothesize that increased
membrane localization of β-catenin will aﬀect cadherin−catenin
interactions between neuronal cells, and modulate intercellular
interactions.
■ METHODS
Cell Culture. NPCs derived from human iPSCs (HIP) were
obtained from GlobalStem. All experiments were carried out in these
NPCs unless described otherwise. 8330 NPCs derived from a control
human iPSC line as described previously were used to show
reproducibility in a second human NPC line.50 NPCs were cultured
in media containing 70% DMEM with high glucose (Life
Technologies), 30% Ham’s F12 with L-glutamine (Cellgro/Medi-
atech), penicillin/streptomycin, and B27 supplement (Life Technol-
ogies) as well as 20 ng/mL epidermal growth factor (EGF) (Sigma-
Aldrich), 20 ng/mL basic ﬁbroblast growth factor (bFGF) (Stemgent),
and 5 μg/mL heparin (Sigma-Aldrich). Plates were coated with 20 μg/
mL poly-L-ornithine (Sigma-Aldrich) solution in ddH2O followed by 5
μg/mL laminin (Sigma-Aldrich) in phosphate-buﬀered saline (PBS)
(Life Technologies).
Western Blots and Immunoprecipitation. Cells were lysed by
boiling in Laemmli sample buﬀer (Bio-Rad) with 5% 2-mercaptoe-
thanol (Sigma-Aldrich). Proteins in the lysate were separated by SDS-
PAGE and transferred to PVDF membrane. The blots were probed
with antibodies against β-catenin (carboxy-terminal antigen) (Cat. No.
9587), phospho-β-catenin (Ser45) (Cat. No. 9564), phospho-β-
catenin (Ser33/Ser37/Thr41) (Cat. No. 9561), Ac-Lys49-β-catenin
(Cat. No. 9030), GAPDH (Cat. No. 2118), and integrin β1 (Cat. No.
4706), which were all obtained from Cell Signaling. The N-cadherin
(Cat. No. 610921) and GSK3β (Cat. No. 61020) antibodies were
obtained from BD Bioscience. The CK1α antibody (Cat. No.
CTX50020) was obtained from GeneTex. Antiubiquitin antibody
(Cat. No. ST1200) and anti-histone-H3 antibody (Cat. No. 06-755)
were obtained from Millipore. Antibodies against Ac-Lys40-α-tubulin
(Cat. No. T7451), α-tubulin (Cat. No. T9026), β-tubulin (Cat. No.
8328), and β-actin (Cat. No. A5441) were obtained from Sigma-
Aldrich. Anti-HDAC6 antibody (Cat. No. SC-11420) was obtained
from Santa Cruz. siRNA reagents were obtained from Thermo
Scientiﬁc. Accell HDAC6 siRNA (Cat. No. EQ-003499-00-0005) and
nontargeting siRNA (D-001910-01-05) were initially diluted in buﬀer
(Cat. No. B-002000-UB-100) to prepare 100 μM solutions and
subsequently diluted to a 1 μM solution in delivery media (Cat. No. B-
005000) supplemented with 20 ng/mL EGF, 20 ng/mL bFGF, and 5
μg/mL heparin. For the knockdown experiments, NPCs were plated at
25% conﬂuency in 96-well plates precoated with poly-L-ornithine and
laminin and incubated overnight. NPC media was then replaced
with100 μL of the HDAC6 siRNA solution incubated for 72 h.
HDAC6 knockdown was assessed by Western blot as well as
immunostaining. For immunoprecipitation experiments, lysates were
incubated with primary antibody and A/G Plus-Agarose beads (Cat.
No. sc-2003, Santa Cruz) overnight at 4 °C. Cell fractionation was
performed using standard protocols as described in the Cell
Fractionation Kit obtained from Cell Signaling. Western blot
quantiﬁcation was performed using ImageJ analysis software.53
Imaging. For immunoﬂuorescence experiments, cells were grown
on glass coverslips coated with 20 μg/mL poly-L-ornithine in ddH2O
followed by 5 μg/mL laminin in PBS, ﬁxed in 4% formalin in PBS for
20 min and permeabilized for 20 min in 0.1% Triton-PBS. Cells were
then blocked with 2% bovine serum albumin (BSA) in PBS for 1 h at
room temperature (RT). Cultures were ﬁrst incubated with primary
antibodies in 2% BSA overnight at 4 °C and then with secondary
antibodies for 1 h at RT in 2% BSA. After washing in PBS, the glass
coverslips were mounted on to glass slides. Images were captured with
AxioPlan microscope (Zeiss) equipped with AxioVision software
(Zeiss). Quantiﬁcation of β-catenin at the plasma membrane was
carried out using CellProﬁler image analysis software, by identifying
and spatially binning the cytoplasm into concentric regions, then
measuring the β-catenin distribution from the outermost bin.54
Sources of Chemicals. HDAC inhibitors CI-994, Cpd-60,
suberoylanilide hydroxamic acid (SAHA), tubacin, tubastatin A,
ACY-1215, and PCI-34051 were purchased from commercial vendors.
Crebinostat and BG-45 were synthesized in house, as described
previously.31,55
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